RT Journal Article
T1 Effects of sardine-enriched diet on metabolic control, inflammation and gut microbiota in drug-naïve patients with type 2 diabetes: a pilot randomized trial.
A1 Balfegó, Mariona
A1 Canivell, Silvia
A1 Hanzu, Felicia A
A1 Sala-Vila, Aleix
A1 Martínez-Medina, Margarita
A1 Murillo, Serafín
A1 Mur, Teresa
A1 Ruano, Elena G
A1 Linares, Francisca
A1 Porras, Nuria
A1 Valladares, Silvia
A1 Fontalba, Maria
A1 Roura, Elena
A1 Novials, Anna
A1 Hernández, Cristina
A1 Aranda, Gloria
A1 Sisó-Almirall, Antoni
A1 Rojo-Martínez, Gemma
A1 Simó, Rafael
A1 Gomis, Ramon
K1 Type 2 diabete
K1 Pilot trial
K1 Nutrition therapy
K1 Oily fish
K1 Sardine
K1 Adiponectina
K1 Grupos control
K1 Diabetes mellitus tipo II
K1 Dieta
K1 Membrana eritrocítica
K1 Escherichia coli
K1 Ayuno
K1 Ácidos grasos omega 3
K1 Firmicutes
K1 Microbiota intestinal
K1 Glucosa
K1 Hemoglobina A glicosilada
K1 Homeostasis
K1 Humanos
K1 Insulina
K1 Resistencia a la insulina
K1 Política nutricional
K1 Terapia nutricional
K1 Proyectos piloto
K1 Prevotella
K1 Factores de riesgo
K1 Bacteroides
K1 Bacteroidetes
K1 Glucosa sanguínea
K1 Enfermedades cardiovasculares
K1 Animales
AB BACKGROUNDNutrition therapy is the cornerstone of treating diabetes mellitus. The inclusion of fish (particularly oily fish) at least two times per week is recommended by current international dietary guidelines for type 2 diabetes. In contrast to a large number of human studies examining the effects of oily fish on different cardiovascular risk factors, little research on this topic is available in patients with type 2 diabetes. The aims of this pilot study were to investigate the effects of a sardine-enriched diet on metabolic control, adiponectin, inflammatory markers, erythrocyte membrane fatty acid (EMFA) composition, and gut microbiota in drug-naïve patients with type 2 diabetes.METHODS35 drug-naïve patients with type 2 diabetes were randomized to follow either a type 2 diabetes standard diet (control group: CG), or a standard diet enriched with 100 g of sardines 5 days a week (sardine group: SG) for 6 months. Anthropometric, dietary information, fasting glycated hemoglobin, glucose, insulin, adiponectin, inflammatory markers, EMFA and specific bacterial strains were determined before and after intervention.RESULTSThere were no significant differences in glycemic control between groups at the end of the study. Both groups decreased plasma insulin (SG: -35.3%, P = 0.01, CG: -22.6%, P = 0.02) and homeostasis model of assessment--insulin resistance (HOMA-IR) (SG: -39.2%, P = 0.007, CG: -21.8%, P = 0.04) at 6-months from baseline. However only SG increased adiponectin in plasma compared to baseline level (+40.7%, P = 0.04). The omega-3 index increased 2.6% in the SG compared to 0.6% in the CG (P = 0.001). Both dietary interventions decreased phylum Firmicutes (SG and CG: P = 0.04) and increased E. coli concentrations (SG: P = 0.01, CG: P = 0.03) at the end of the study from baseline, whereas SG decreased Firmicutes/Bacteroidetes ratio (P = 0.04) and increased Bacteroides-Prevotella (P = 0.004) compared to baseline.CONCLUSIONSAlthough enriching diet with 100 g of sardines 5 days a week during 6 months to a type 2 diabetes standard diet seems to have neutral effects on glycemic control in drug-naïve patients with type 2 diabetes, this nutritional intervention could have beneficial effects on cardiovascular risk. Furthermore, both dietary interventions decreased HOMA-IR and altered gut microbiota composition of drug-naïve patients with type 2 diabetes.TRIAL REGISTRATIONTrial number and name of the registry: NCT02294526, ClinicalTrials.gov.
PB Public Libray of Science
YR 2016
FD 2016-04-18
LK http://hdl.handle.net/10668/2405
UL http://hdl.handle.net/10668/2405
LA en
NO Balfegó M, Canivell S, Hanzu FA, Sala-Vila A, Martínez-Medina M, Murillo S, et al. Effects of sardine-enriched diet on metabolic control, inflammation and gut microbiota in drug-naïve patients with type 2 diabetes: a pilot randomized trial. Lipids Health Dis. 2016; 15:78
NO Journal Article; Research Support, Non-U.S. Gov't; Trial number and name of the registry: NCT02294526, ClinicalTrials.gov.
DS RISalud
RD Apr 18, 2025